Nuvo Pharmaceuticals Inc NRIFF

Boring Making Money

[Schaffhausen]

Since the split of Crescita from NRI, the Nuvo shares by themselves are worth more than the pre-split combined price of the two stocks together. At today's prices of NRI and CTX, staying invested in both companies since the split has netted over 25% return in less than 8 weeks. My prognostications are coming to fruition quickly. The combined value of Nuvo and Crescita never dipped below the pre-split value, but we all knew that would be the case from the pre-split trading patterns. Looking forward, just a little more time and the real value will begin to swell. Nuvo is going in the right direction. It's a challenge to find comparable undervalued companies with such revenue stability, high growth prospects and clean balance sheet. NRI doesn't even register a Price/Earnings-to-growth ratio in the current trading range! Absurd. I expect $10+ by August. Crescita is about as good a speculative hold as any. Not much downside at $1.60 since it has a cash hoard equivalent of over $3.00 per share together with a dogs breakfast of pipeline drug candidates and strong patents. I'm hopeful that Crescita can be liquidated for at least cash value. I have to say, it's nice to finally be making money on NRI, however, it's is way less exciting around here now. Oh well, take the good with the bad. Cheers, Schaff